Merck & Co., Inc. (MRK)
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports
Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma, the Financial Times reported on Wednesday.
Merck & Co.: A Pharma Titan At A Discount
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its current market price, MRK is as much as 23% undervalued. Underlying fundamentals are still strong, with great margins, heavy R&D investing, and a plan to aggressively expand by CapEx spending totaling $20 billion from 2024 to 2028.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
